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Plasmodium falciparum erythrocyte membrane
protein-1 (PfEMP-1) is a variable antigen ex-
pressed by P. falciparum, the malarial parasite.
PfEMP-1, present on the surface of infected
host erythrocytes, mediates erythrocyte bind-
ing to vascular endothelium, enabling the para-
site to avoid splenic clearance. In addition,
PfEMP-1 is proposed to regulate host immune
responses via interactions with the CD36 recep-
tor on antigen-presenting cells. We investigated
the immunoregulatory function of PfEMP-1 by
comparing host cell responses to erythrocytes
infected with either wild-type parasites or trans-
genic parasites lacking PfEMP-1. We showed
that PfEMP-1 suppresses the production of
the cytokine interferon-g by human peripheral
blood mononuclear cells early after exposure
toP. falciparum. Suppression of this rapid proin-
flammatory response was CD36 independent
and specific to interferon-g production by gd-T,
NK, and ab-T cells. These data demonstrate a
parasite strategy for downregulating the proin-
flammatory interferon-g response and further esta-
blish transgenic parasites lacking PfEMP-1 as
powerful tools for elucidatingPfEMP-1 functions.
INTRODUCTION
The multidomain variant antigen Plasmodium falciparum
Erythrocyte Membrane Protein-1 (PfEMP-1), expressed
on the surface of P. falciparum-infected erythrocytes,
can mediate binding to CD36, intercellular adhesion
molecule-1, vascular cell adhesion molecule, E-selectin,
P-selectin, CD31, and chondroitin sulfate A (CSA) on vas-
cular endothelial cells, thus enabling the parasite to avoid
splenic clearance (Newbold, 1999). PfEMP-1 is encoded
by the var gene family, which has been divided into three
major groups (A, B, and C) based on genomic location130 Cell Host & Microbe 2, 130–138, August 2007 ª2007 Elsevieand upstream sequence (Ups). Group B and C var genes
typically bind CD36, whereas group A var genes generally
do not (Robinson et al., 2003). Furthermore, group B andC
var genes tend to be associated with asymptomatic
malaria, while group A var genes have been implicated
in cerebral malaria (Kyriacou et al., 2006). The extensive
var repertoire and allelic diversity within PfEMP-1 enable
the parasite to evade humoral immunity while maintaining
cytoadherence to blood vessel walls (Hisaeda et al.,
2005). Although successful in evading antibody re-
sponses, PfEMP-1 is also proposed to modulate host im-
mune responses via CD36-dependent interactions with
antigen-presenting cells. Phagocytosis of nonopsonized
infected erythrocytes by macrophages was shown to be
dependent on CD36 ligation and was inhibited by the pro-
teolytic removal of PfEMP-1 (McGilvray et al., 2000). Fur-
thermore, infected erythrocytes inhibited DC maturation,
reducing the capacity of DC to activate T cells (Urban
et al., 1999). This was proposed to result from PfEMP-1
binding to CD36, thus implicating the CD36-binding
cysteine interdomain region-1a (CIDR-1a) domain of
PfEMP-1 as mediating this effect (Urban et al., 2001b).
In contrast, however, addition of recombinant CIDR-1a
to cultures of naive human PBMC resulted in the poly-
clonal activation of naive CD4 T cells and NK cells and
induced IFN-g production, leading to the suggestion that
this molecule may contribute to inflammatory immuno-
pathogenesis (Ndungu et al., 2006). These inconsistencies
may reflect methodological constraints that have previ-
ously restricted immunological analyses of PfEMP-1 to
use of either nonisogenic parasites selected for specific
adhesion phenotypes (Urban et al., 1999) (whereby uni-
form expression of one PfEMP-1 allele in the population
is not assured); or on recombinant PfEMP-1 subdomains
expressed in E. coli (Allsopp et al., 2002; Joergensen
et al., 2006; Ndungu et al., 2006), which may be con-
founded by misfolding, glycosylation, LPS contamination,
presentation out of cellular context, and application in
physiologically inappropriate concentrations. Clearly,
PfEMP-1 constitutes a major interface between parasite
and host, and the immunoregulatory activities of this mol-
ecule are likely to be important (Urban et al., 2005). Fur-
thermore, as PfEMP-1 domains may be developed asr Inc.
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PfEMP-1 Suppresses Early IFN-g ProductionFigure 1. PfEMP-1 Suppresses the Innate IFN-g Response of
PBMC to P. falciparum In Vitro
uRBC, parental 3D7, and 3D7 PfEMP-1 knockdown parasites were
solubilized in 1% Triton X-100. The insoluble fraction was then solubi-
lized in 2% SDS, and the supernatant was probed in western blot with
antibodies (mAb 6H1) against the conserved intercellular region of
PfEMP-1 (A). Parental 3D7 shows a distinctive band above 250 kDa,
typical of PfEMP-1, whereas 3D7 PfEMP-1 iRBC and uRBC do not
(asterisks denote erythrocyte proteins) (A). (B) is a vector map of the
construct used to produce the 3D7 PfEMP-1 line containing the hu-
man dihydrofolate reductase (hDHFR) gene that encodes resistance
to WR99210. The expression of hDHFR is under the control of a var
upsC gene promoter. The blasticidin deaminase (BSD) gene encodes
resistance to blasticidin-S and serves to maintain stable integration
of the plasmid in the parasite chromosome. PBMC (2 3 105) from a
number of malaria-naive donors were stimulated for 24 hr with
6 3 105 3D7 parental iRBC, 3D7 PfEMP-1 iRBC, or uRBC (C), or
6 3 105 3D7 parental iRBC, trypsin-digested 3D7 parental iRBC,
uRBC, or trypsin-digested uRBC (D). Supernatants were harvested
and assayed for cytokines. The mean IFN-g detected in supernatants
is shown (C andD). Error bars are the SEM forR2 experiments. Upper-
case letters indicate donors. In 9/9 donors, the mean level of IFN-gCell Hoshumoral vaccines (Baruch et al., 2002), understanding
their potential role in the promotion or prevention of im-
munoregulation, immunopathology, and cell-mediated
immunity is a priority. Therefore, to investigate the immu-
nological function of endogenous, whole PfEMP-1, ex-
pressed in situ in the correct context and concentration
on the parasite surface, we used transgenic parasite lines
that lack surface expression of PfEMP-1 (Maier et al.,
2006; Voss et al., 2006). Using these parasite lines, we
demonstrate that PfEMP-1 suppresses innate IFN-g pro-
duction by naive gd-T cells and NK cells, as well as early
IFN-g production by naive ab-T cells. No evidence for
PfEMP-1-mediated polyclonal activation of these cell
populations was found. The interaction of CD36 with
CIDR-1a, proposed variously tomediate immunosuppres-
sion (Urban et al., 1999, 2001a) or polyclonal activation of
naive T cells and NK cells (Ndungu et al., 2006), was not
required for the suppression of IFN-g production. There-
fore, PfEMP-1-mediated suppression of innate IFN-g
production occurs via a CIDR-1a/CD36-independent
pathway. Furthermore,PfEMP-1was neither a suppressor
nor an activator of malaria-induced NK cell- or T cell-
mediated cytolysis. These data demonstrate a strategy
employed by the parasite to downregulate the proinflam-
matory IFN-g response and validate the use of PfEMP-1
transgenic parasites as powerful tools for dissecting the
functional and immunological roles of this important viru-
lence protein in human malaria.
RESULTS AND DISCUSSION
PfEMP-1 Suppresses the Innate IFN-g Response
to Malaria
To assess the role of PfEMP-1 in the regulation of cellular
immune responses to malaria, transgenic parasites lack-
ing surface expression of PfEMP-1 were used (Maier
et al., 2006; Voss et al., 2006). As shown in Figure 1A,
P. falciparum 3D7 parental parasites express PfEMP-1,
whereas the 3D7 PfEMP-1 knockdown parasites do not.
This is due to the expression of a human dihydrofolate
reductase gene, which confers resistance to WR99210,
under the control of a var upsC gene promoter that allows
infiltration of the antigenic variation program, thus silenc-
ing the gene family (Voss et al., 2006) (Figure 1B). To inves-
tigate the effect of the absence and presence of PfEMP-1
on human, innate cellular immune responses, peripheral
blood mononuclear cells (PBMC) from healthy, malaria-
naive adult donors were stimulated for 24 hr with 3D7 pa-
rental, live P. falciparum schizont-infected red blood cells
(iRBC), 3D7 PfEMP-1 iRBC, or uninfected red blood cells
(uRBC), and their ability to induce proinflammatory
and anti-inflammatory cytokines was observed. Loss of
produced by PBMC following stimulation with 3D7 PfEMP-1 iRBC
exceeds that for 3D7 parental iRBC (p < 0.01; nonparametric sign
test) (C). Similarly, in 7/7 donors, the mean level of IFN-g produced
by PBMC following stimulation with trypsin-digested 3D7 parental
iRBC exceeds that for nondigested 3D7 parental iRBC (p < 0.01; non-
parametric sign test) (D).t & Microbe 2, 130–138, August 2007 ª2007 Elsevier Inc. 131
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in all donors compared to parental iRBC, with some do-
nors producing up to four timesmore IFN-g in the absence
of PfEMP-1 (Figure 1C), thus suggesting that PfEMP-1
suppresses the host innate IFN-g response tomalaria. Pa-
rental 3D7 iRBC that were digested with trypsin to remove
PfEMP-1 proteolytically also induced significantly higher
IFN-g production compared to nondigested iRBC
(Figure 1D), confirming that the differences in the ability
of the parental and transgenic iRBC to induce IFN-g are
not due to differences in parasite maturation or a conse-
quence of the introduction of the plasmid. In addition,
knockdown ofPfEMP-1 does not affect expression or traf-
ficking of any other known infected erythrocyte surface
proteins (T.S.V. and A.F.C., unpublished data). Further-
more, loss of PfEMP-1 had no effect on TNF-a, IL-6,
IL-10, IL-2, or IL-4 production by PBMC (Figure S1 in the
Supplemental Data available with this article online).
Therefore, the suppressive effect of PfEMP-1 appears
to be specific for pathways responsible for innate IFN-g
output.
PfEMP-1 Negatively Regulates IFN-g Production
by gd-T, NK, and ab-T Cells
We and others have previously shown that IFN-g is rapidly
produced by gd-T cells, NK cells, and ab-T cells following
stimulation of naive human PBMC with iRBC (Artavanis-
Tsakonas and Riley, 2002; D’Ombrain et al., 2007; Hen-
smann and Kwiatkowski, 2001). We have further demon-
strated that, in the majority of donors, gd-T cells are the
predominant source of early IFN-g, while NK cells and
ab-T cells make only minor contributions (D’Ombrain
et al., 2007). To identify which early IFN-g-producing cell
types are suppressed by PfEMP-1, PBMC were stimu-
lated for 24 hr with 3D7 parental iRBC, 3D7 PfEMP-1
iRBC, or uRBC, harvested, and stained for intracellular
IFN-g in combination with CD3, gdTCR, and CD56. gd-T
cells (CD3+gdTCR+), NK cells (CD3CD56+), and to
a lesser extent ab-T cells (CD3+gdTCR), were each neg-
atively regulated by PfEMP-1 with respect to early IFN-g
production (Figure 2). These results contrast with previous
studies that found recombinant CIDR-1a (a subdomain of
PfEMP-1) caused the polyclonal activation of NK cells and
CD4 T cells to produce IFN-g (Allsopp et al., 2002; Ndungu
et al., 2006). Furthermore, recombinant CIDR-1awas also
found to induce IL-10 production by PBMC-derived DC
(Allsopp et al., 2002; Ndungu et al., 2006); however, the
PfEMP-1 null transgenic iRBC had no effect on IL-10 out-
put from PBMC (Figure S1). The use of recombinant pro-
teins expressed in either bacterial or mammalian cells
may be subject to effects arising from glycosylation, LPS
contamination, molar ratio/concentration dependence ef-
fects, misfolding, and expression out of appropriate cellu-
lar context. In contrast, the isogenic parasite lines used in
the present study differ only in the presence or absence of
surface PfEMP-1, which is expressed in situ in the correct
context and concentration on the iRBC surface. Further-
more, recombinant CIDR-1awas used at 5 mg/ml (Allsopp
et al., 2002; Ndungu et al., 2006), or 1.83 107 M. Assum-132 Cell Host & Microbe 2, 130–138, August 2007 ª2007 Elseviing PfEMP-1 has 5000 copies/cell, the concentration or li-
gand density of native PfEMP-1 in standard costimulation
assays is approximately 2.53 1011 M, 72,000 times less
than that used in the recombinant protein studies. Impor-
tantly, the change in phenotype upon loss of PfEMP-1 in
the present study indicates bioactivity at physiological
levels of expression.
PfEMP-1 Modulates Innate IFN-g Production
via a CD36-Independent Pathway
The simultaneous negative regulation of IFN-g production
by gd-T cells, NK cells, and ab-T cells (Figure 2) suggests
Figure 2. PfEMP-1 Negatively Regulates Early IFN-g Produc-
tion by gd-T, NK, and ab-T Cells
PBMC (2 3 105) from eight malaria-naive donors were stimulated
for 24 hr with 6 3 105 3D7 parental iRBC, 3D7 PfEMP-1 iRBC, or
uRBC. PBMC were harvested and stained for intracellular IFN-g,
gdTCR, CD3, and CD56. IFN-g+ cells were gated (A) and identified
as CD3CD56+ NK cells (B), CD3+gdTCR+ gd-T cells (C), or
CD3+gdTCR ab-T cells (C). FACS plots in (A)–(C) are from one repre-
sentative donor. FACS data from all eight donors is displayed graphi-
cally in (D) (uppercase letters indicate donors).er Inc.
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Binding of the CIDR-1a domain of PfEMP-1 to CD36 has
been proposed to mediate the reduction in the capacity
of DC to stimulate secondary T cell responses following
parasite stimulation (Urban et al., 1999, 2001b). Further-
more, phagocytosis of nonopsonized infected erythro-
cytes by macrophages was shown to be dependent on
CD36 (McGilvray et al., 2000). Thus, we sought to deter-
mine whether the PfEMP-1-mediated negative regulation
of IFN-g production by gd-T cells, NK cells, and ab-T cells
requires the CIDR-1a/CD36 receptor-ligand interaction.
This hypothesis was tested using the CS2 strain of P. fal-
ciparum, which, unlike 3D7, expresses the var2CSA
PfEMP-1, which lacks a CIDR-1a domain and binds to
CSA but not CD36 (Figure 3). Consequently, CD36-depen-
dent pathways are not initiated by CS2 parasites. PBMC
were stimulated as previously with CS2 parental iRBC,
CS2 Skeletal Binding Protein-1 (SBP-1) KO iRBC (which
lack expression of PfEMP-1 on the infected erythrocyte
surface) (Maier et al., 2006), or uRBC. As shown in Figure 3,
the CS2 parental and SBP-1 KO PfEMP-1 iRBC recapit-
ulate the results obtained with the 3D7 parental and 3D7
PfEMP-1 iRBC (Figure 1), with one donor producing
19.6-foldmore IFN-g in the absence ofPfEMP-1 (Figure 3).
Clearly, suppression of IFN-g production by PfEMP-1 oc-
curs via a pathway independent of CIDR-1a/CD36 inter-
actions. The PfEMP-1 domain that mediates suppression
of IFN-g is likely to be conserved between 3D7 and CS2
and thus may involve a Duffy binding-like (DBL) domain.
We are currently creating PfEMP-1 null parasites express-
ing defined PfEMP-1 domains to identify the molecular
basis of PfEMP-1 immunoregulatory activity and to iden-
tify the corresponding host receptor.
PfEMP-1 Is Not a Ligand for NK Cell
or T Cell Cytotoxicity
In addition to cytokine production, NK cells, CD8+CD4
gd-T cells, and CD8+ ab-T cells also possess cytotoxic ca-
pabilities. gd-T cells have been shown to be cytotoxic for
iRBC, while CD8 T cells are not, due to the lack of MHC
class I expression on iRBC (Troye-Blomberg et al.,
1999). LAMP-1 (CD107a) appears on the surface of effec-
tor cells following degranulation and can be used as
amarker of cytotoxic activation (Alter et al., 2004). NK cells
have previously been reported to lyse iRBC (Chaicumpa
et al., 1983; Orago and Facer, 1991) and induce expres-
sion of LAMP-1 following exposure to iRBC (Korbel
et al., 2005). Slight changes in NK cell activation status
were detected after incubation with peptidic DBL-1a (a
PfEMP-1 subdomain) which was proposed to bind the
Natural Cytotoxicity Receptors NKp30 and NKp46 and in-
duce NK cell cytotoxicity (Mavoungou et al., 2007). In that
study, DBL-1a peptides were used at 40 mg/well, or
around 23 10423 105 M, assuming a peptide molec-
ular mass of approximately 2200 Daltons. This is approx-
imately 2–10 million times greater than the ligand density
of native PfEMP-1 on the surface of iRBC. Therefore, we
sought to test the role of PfEMP-1 in NK cell cytotoxicity
further using isogenic parasites differing only in the pres-Cell Hoence or absence of PfEMP-1 expressed in situ in the cor-
rect context and concentration on the iRBC surface. A role
for PfEMP-1 in gd-T cell cytotoxicity was also explored.
Accordingly, we compared the ability of 3D7 parental
iRBC or 3D7 PfEMP-1 iRBC to induce LAMP-1 expres-
sion on NK cells and T cells following 6 hr of coculture
with PBMC from healthy, malaria-naive adult donors.
The K562 cell line, a well-defined target for NK cell cyto-
toxicity, was used as a positive control, while uRBC
served as the negative control. LAMP-1 was expressed
at high levels on NK cells and at modest levels on T cells,
Figure 3. PfEMP-1 Modulates Innate IFN-g Production via
a CD36-Independent Pathway
The western blot (prepared as for Figure 1A) confirms that parental
CS2 expresses PfEMP-1 on the infected erythrocyte surface, whereas
DSBP-1KO PfEMP-1 does not (A). The typical PfEMP-1 extracellular
domain from a CD36-binding 3D7 parental parasite is shown in (B)
(Robinson et al., 2003). The CIDR-1a domain of PfEMP-1 mediates
binding to CD36 (Baruch et al., 1999). The extracellular domain of var2-
CSA, the predominant PfEMP-1 protein expressed by CS2 parental
parasites that mediates CSA binding, is illustrated in (C) (Gardner
et al., 2002). Note the absence of a CIDR-1a domain in var2CSA
PfEMP-1 (C), rendering this parasite unable to bind CD36 (Gardner
et al., 2002). PBMC (23 105) from ten malaria-naive donors were stim-
ulated for 24 hr with 63 105 CS2 parental iRBC,DSBP-1KO PfEMP-1
iRBC, or uRBC. Supernatants were harvested and assayed for IFN-g.
Themean IFN-g detected in supernatants from ten donors is shown (D).
Error bars are the SEM forR2 experiments. In 10/10 donors, the mean
level of IFN-g produced by PBMC following stimulation with DSBP-
1KO PfEMP-1 iRBC exceeds that for CS2 parental iRBC (p < 0.001;
nonparametric sign test). Upper case letters indicate donors.st & Microbe 2, 130–138, August 2007 ª2007 Elsevier Inc. 133
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PfEMP-1 Suppresses Early IFN-g ProductionFigure 4. PfEMP-1 Is Not a Ligand for Malaria-Induced NK Cell or T Cell Cytotoxicity
PBMC (23 105) were cultured for 6 hr in the presence of 63 105 K562 cells, 3D7 parental iRBC, 3D7PfEMP-1 iRBC, or uRBC. PBMCwere harvested
and stained for CD3, CD56, and the cytotoxicity marker LAMP-1. CD3CD56+ NK cells and CD3+ T cells were gated (A) and analyzed for LAMP-1
expression in response to each treatment (B). FACS plots in (A) and (B) are from one representative donor. Mean LAMP-1 expression on NK cells
and T cells from ten donors is shown in (C) and (D), respectively. Error bars are the SEM for ten donors. p values from Student’s t tests show no
statistically significant differences between LAMP-1 expression on NK cells or T cells stimulated with 3D7 parental iRBC or 3D7 PfEMP-1 iRBC
(C and D).following incubation with K562 target cells (Figure 4). Fur-
thermore, LAMP-1 expression was detected above back-
ground levels on both NK cells and T cells following incu-
bation with 3D7 parental iRBC and 3D7 PfEMP-1 iRBC
(Figure 4). Importantly, no statistically significant differ-
ences between LAMP-1 expression levels on NK cells or
T cells stimulated with 3D7 parental or 3D7 PfEMP-1
iRBC were detected (Figure 4), thus demonstrating that
PfEMP-1, inclusive of a DBL-1a subdomain and ex-
pressed under physiologically relevant conditions, is not
a ligand for NK cell-mediated or T cell-mediated cytotox-
icity of iRBC.
Conclusions
Plasmodium falciparum causes rapid activation of macro-
phages and DC through the production of pathogen-
associated molecular patterns, such as glycosylphospha-
tidylinositol (Schofield and Hackett, 1993) and malarial134 Cell Host & Microbe 2, 130–138, August 2007 ª2007 ElsevDNA (associated with haemozoin) (Parroche et al., 2007),
which act through Toll-like receptors (Krishegowda
et al., 2005; Parroche et al., 2007; Zhu et al., 2005). Sub-
sequently, NK receptor- and gdTCR-dependent innate
and ‘‘intermediate’’ adaptive pathways become activated,
resulting in rapid production of the proinflammatory cyto-
kine IFN-g (Schofield and Grau, 2005). Following 24 hr
stimulation of human PBMC with live P. falciparum-
infected erythrocytes, gd-T cells expressing NK receptors
represent the major cellular source of innate IFN-g, with
minor contributions from NK cells and ab-T cells
(D’Ombrain et al., 2007). The activating ligand for NK cells
remains to be identified, while gd-T cells are known to be
activated by malarial phosphoantigens (Behr et al., 1996;
Pichyangkul et al., 1997) and rapid activation of naive
ab-T cells by P. falciparum is thought to be due to the
presence of cross-reactive antigens that are expressed
on a wide range of common microbes (Currier et al.,ier Inc.
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PfEMP-1 Suppresses Early IFN-g Production1992; Zevering et al., 1992). Here we have identified an im-
munoregulatory mechanism of P. falciparum whereby the
early IFN-g response of gd-T cells, NK cells, and ab-T cells
is strongly suppressed by the presence of PfEMP-1.
The host receptor(s) utilized by PfEMP-1 to suppress
IFN-g production by gd-T, NK, and ab-T cells remains to
be identified; however, this pathway is independent of
CIDR-1a/CD36 interactions and thus occurs via a different
mechanism than that proposed for PfEMP-1 interactions
with DC and macrophages (McGilvray et al., 2000; Urban
et al., 1999, 2001b). As plasmacytoid DC promote early
gd-T cell activation (Pichyangkul et al., 2004), myeloid
DC stimulate malaria-specific ab-T cells (Urban et al.,
1999), and both macrophages and myeloid DC are re-
quired for NK cell activation (Baratin et al., 2005; Newman
et al., 2006), it is unlikely that PfEMP-1 suppresses early
IFN-g production via a common antigen-presenting cell.
Furthermore, the effect of PfEMP-1 is specific to IFN-g,
with no effect on a range of proinflammatory and anti-
inflammatory cytokines, including those typically asso-
ciated with macrophage and DC activation. Therefore, it
is plausible that PfEMP-1 may signal directly to gd-T cells,
NK cells, and ab-T cells via a common receptor.
Interestingly, in humans, malaria-responsive gd-T and
NK cells more frequently express the inhibitory NK recep-
tor NKG2A (Artavanis-Tsakonas et al., 2003; D’Ombrain
et al., 2007). Thus, PfEMP-1 may engage NKG2A (and/
or other inhibitory NK receptors), resulting in suppression
of IFN-g production. Alternatively, the host receptor may
be a more general, non-NK receptor that negatively regu-
lates leukocyte activation. The suppression of IFN-g by
PfEMP-1 appears to be due to a PfEMP-1 domain that
is conserved between 3D7 and CS2 parasite lines and
thus may involve a DBL domain. We are currently creating
PfEMP-1 null parasites expressing defined PfEMP-1 do-
mains to identify both the PfEMP-1 subdomain and the
corresponding host receptor that mediates innate IFN-g
suppression.
The suppression of early IFN-g production by PfEMP-1
was quantitatively highly significant (up to 20-fold). Given
the dual role of IFN-g in malaria protection and pathogen-
esis, these data raise the possibility that this process
might impact either IFN-g-dependent antiparasite immu-
nity or IFN-g-dependent immunopathogenesis. For exam-
ple, protection against reinfection with P. falciparum ma-
laria has been associated with higher plasma levels of
IFN-g (Luty et al., 1999), possibly resulting from increased
macrophage activation and enhanced parasite clearance
(Hisaeda et al., 2005). Furthermore, in the P. chabaudimu-
rine model of malaria, ifn-g/ and ifn-g receptor/ mice
exhibit higher mortality rates (Favre et al., 1997; Su and
Stevenson, 2000), while in the P. berghei-K173 murine
model of malaria, a 24 hr IFN-g peak, not observed in
the closely related P. berghei-ANKA cerebral malaria
model, was associated with protection from the cerebral
syndrome (Mitchell et al., 2005). The suppression of early
IFN-g production by PfEMP-1, therefore, may represent
an immune evasion strategy employed by P. falciparum,
which serves to downregulate the antiparasitic IFN-gCell Hosresponse. Furthermore, IFN-g inhibits the infectivity of
P. berghei sporozoites for hepatocytes in mice and rats
and is a critical effector mechanism in immunity to liver
stage infection (Schofield et al., 1987a, 1987b). It is thus
plausible that the suppression of IFN-g by PfEMP-1 may
also favor reinfection upon subsequent sporozoite chal-
lenge in humans. However, although critical in protective
antimalarial immunity, IFN-g may also play an important
role in pathogenesis. In humans, polymorphisms in both
IFN-g and IFN-g Receptor 1 genes are associated with
severe malaria (Kwiatkowski, 2005), and high levels of
circulating IFN-g were found to be indicators of poor
prognostic outcome (Hunt and Grau, 2003). Similarly, in
the P. berghei-ANKA model of cerebral malaria, neutrali-
zation of IFN-g in vivo prevents fatalities (Grau et al.,
1986), and ifn-g/ and ifn-g receptor/ mice fail to de-
velop the cerebral syndrome (Amani et al., 2000). The sup-
pression of IFN-g by PfEMP-1 may thus also be beneficial
for the host, possibly serving to reduce the severity of clin-
ical symptoms and immunopathogenesis. Clearly, the role
of IFN-g in malaria protection and pathogenesis is com-
plex and needs to be addressed in the context of ade-
quate epidemiological study designs. Therefore, to allow
the impact of PfEMP-1-mediated immune regulation to
be assessed in relation to relevant parasitological and clin-
ical outcome variables, we are currently conducting longi-




Blood from healthy nonimmune adults was obtained from the Austra-
lian Red Cross Blood Service under appropriate ethical approval.
Blood was diluted 1:1 in PBS, and PBMC were separated by density
centrifugation with Ficoll-Paque PLUS (Amersham Biosciences, Swe-
den). PBMC were washed and resuspended in complete medium
(RPMI 1640, 5% heat-inactivated FBS, 2 mM L-glutamine, 25 mM
HEPES, 50 mM 2-ME, 100 U/ml penicillin, and 100 mg/ml streptomycin
sulfate) for use in cytokine induction and LAMP-1 cytotoxicity assays.
Cultivation of P. falciparum
3D7, CS2, and transgenic P. falciparum parasites were cultivated at
37Cwith 5%CO2, 1%O2, and 1%N2 in 150 cm
2 flasks at 4% hemat-
ocrit using O+ human erythrocytes (Australian Red Cross Blood
Service [ARCBS]) in RPMI 1640 buffered with 25 mM HEPES and sup-
plemented with 0.5% Albumax II, 2 mg/ml glucose, 28 mM sodium
bicarbonate, 25 mg/ml gentamycin, and 100 mg/ml hypoxanthine.
Parasite development was monitored by light microscopy using
methanol-fixed, Giemsa-stained thin blood films. The construct used
to produce the transgenic 3D7 PfEMP-1 parasite line was made by
transfecting 3D7 with pHBupsCR (Voss et al., 2006). The blasticidin de-
aminase gene serves to maintain stable integration of the plasmid in
the parasite chromosome. 3D7 PfEMP-1 parasites were cultured
with 4 mg/ml blasticidin-S and 4 nMWR99210 (Voss et al., 2006). Tryp-
sin-digested 3D7 parental iRBC were included as an additional control
for the absence of PfEMP-1. Trypsin digestion of live iRBCwas carried
out as previously described (Beeson et al., 2000). Parasites were
sorbitol synchronized, knob selected, and screened for mycoplasma
negativity. iRBC were purified by magnetic cell sorting CS columns
(Miltenyi Biotec, CA) and resuspended in complete medium for use
in cytokine induction and LAMP-1 cytotoxicity assays.t & Microbe 2, 130–138, August 2007 ª2007 Elsevier Inc. 135
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Immunoblot analysis was performed using iRBC purified by magnetic
cell sorting CS columns (Miltenyi Biotech, CA). iRBC (13 107) were ex-
tracted with 150 ml of 1% (v/v) Triton X-100 in PBS and protease inhib-
itors (Roche). The Triton X-100 insoluble pellet was then extracted with
2% SDS (w/v) and loaded onto the gel in reducing SDS sample buffer
(Baruch et al., 2002).
Cytokine Induction Assay
In 96-well plates, 23 105 PBMC were stimulated with 63 105 live pa-
rental, trypsin-digested parental, or transgenic iRBC, or 63 105 uRBC
per well. Cultures were incubated for 24 hr (37C, 5% CO2). Golgistop
(BD PharMingen) was added at 20 hr. Cells were harvested and ana-
lyzed by flow cytometry. Culture supernatants were analyzed for cyto-
kine content by ELISA and Cytometric Bead Array (BD PharMingen).
IFN-g ELISA
IFN-g was detected in culture supernatants by standard sandwich
ELISA. Purified mouse anti-human IFN-g (NIB42) mAb was used for
capture, and biotinylated mouse anti-human IFN-g (4S.B3) was used
for detection (BD Biosciences, CA).
Detection of TNF-a, IL-6, IL-10, IL-2, and IL-4
TNF-a, IL-6, IL-10, IL-2, and IL-4 were detected in supernatants from
the cytokine induction assays of five donors using the BD Cytometric
Bead Array Human Th1/Th2 Cytokine Kit II (BD Biosciences, CA)
according to the manufacturer’s instructions. Samples were analyzed
in a FACSCalibur flow cytometer (BD Biosciences, CA). Data analysis
was performed with the BD Cytometric Bead Array Software (BD
Biosciences, CA).
LAMP-1 Cytotoxicity Assay
K562 cells (ATCC, Manassas, VA) were maintained at 37C and 5%
CO2 in IMDM supplemented with 4 mM L-glutamine, 1.5g/l sodium bi-
carbonate, and 10% FBS. In 96-well plates, 23 105 PBMC were stim-
ulated with 6 3 105 parental or transgenic iRBC, K562, or uRBC cells
per well. Cultures were incubated for 6 hr (37C, 5% CO2). Golgistop
(BD PharMingen) was added after 1 hr. Cells were harvested and ana-
lyzed for LAMP-1 expression by flow cytometry.
Flow Cytometry
Anti-TCR-g/d FITC, CD3-APC, CD56-biotin (conjugated with Strepta-
vidin-PerCP-Cy5.5), IFN-g-PE, IgG1l isotype control-PE, CD107a
(LAMP-1)-biotin (conjugated with Streptavidin-PerCP-Cy5.5), and
CD56-PE (BD Biosciences, CA) were used for surface, intracellular,
or isotype control staining according to the manufacturer’s recom-
mendations. PBMC were surface stained for 40 min with appropriate
combinations of labeled mAbs. For biotin-labeled antibodies, there
was a second 40 min incubation for conjugation with fluorescently la-
beled streptavidin. PBMC from cytokine induction assayswere stained
for intracellular IFN-g using the BD Cytofix/Cytoperm Kit (BD Biosci-
ences, CA) according to the manufacturer’s instructions, with appro-
priate isotype-matched controls. Finally, cells were resuspended in
200 ml PBS and analyzed in a FACSCalibur flow cytometer (BD Biosci-
ences, CA). Dead cells were gated out by forward and side scatter, and
100,000 live cell events were collected. Data analysis was performed
with Weasel v2.2.3 software.
Statistical Analyses
Nonparametric sign tests were used to determine statistically signifi-
cant differences in IFN-g production between parental and transgenic
iRBC as well as between nontreated parental and trypsin-digested
parental iRBC at the population level (Lehmann, 1975). As the Central
Limit Theorem applied, Student’s t tests were used to determine sta-
tistically significant differences in LAMP-1 expression between paren-
tal and transgenic iRBC.136 Cell Host & Microbe 2, 130–138, August 2007 ª2007 ElseviSupplemental Data
The Supplemental Data include one supplemental figure and can be
found with this article online at http://www.cellhostandmicrobe.com/
cgi/content/full/2/2/130/DC1/.
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